



Owen Garrick, MD MBA

Owen Garrick, MD MBA is President & Chief Executive Officer of Bridge Clinical Research. At Bridge Clinical, Dr. Garrick, has responsibility for the Clinical Trials, Research Analytics, Health Services Research and Healthcare Communications business units. Bridge Clinical is a global private equity-backed contract research and health communications firm focused on drug development, scientific advancement and patient engagement. It is active in multiple therapeutic areas including anti-infectives, autoimmune, cardiovascular disease, endocrinology and oncology. Since 2009, therapies that it has helped developed have generated more than \$6 billion in revenues. In addition to profit & loss responsibility for the business units, Dr. Garrick has oversight of all financial, administrative, and legal aspects of the company, and serves on the Board of Directors. He led Bridge Clinical's expansion into multiple therapeutic areas, launched the public relations arm and represents Bridge Clinical at the US Food & Drug Administration. Dr. Garrick joined the company as Chief Financial Officer and previous to assuming his current position was Chief Operating Office of the company.

Prior to joining Bridge Clinical, Dr. Garrick was Director of Strategy and Business Development at McKesson Corporation, the leader in drug distribution and health information technology. Some of his key accomplishments included the \$450M acquisition of D&K Healthcare which involved due diligence, negotiations and Federal trade Commission (FTC) clearances. He also led the launch of McKesson's Generic Drugs Telesales Business, the development and launch of McKesson's Drug Adherence Business and the expansion of the pharmaceutical packaging business.

Before joining McKesson, Dr. Garrick was Global Head of M&A Negotiations at Novartis Pharmaceuticals. In this position he oversaw small and medium size company acquisitions, equity/license right deals, mature product divestments, and venture investments in biotechnology companies. While at Novartis, he pioneered the contingent payment deal structure with the \$465 million acquisition of Idenix Pharmaceuticals which launched Novartis' Anti-Infectives business unit. This structure has become an industry standard tool in life sciences deals.

Dr. Garrick's experience also includes positions at Goldman Sachs as an investment advisor working with private healthcare companies as they sought to grow, raise capital, and perform initial public offerings and Merck & Company where he authored the first commercial analysis of Human Papillomma Virus vaccine (Gardasil) which has had peak sales of \$1.6 Billion.

Dr. Garrick is a nationally recognized leader in the field of research and research ethics. He was confirmed and completed a term as a member of the Department of Health and Human Services Advisory Council on Human Research Protections from 2012-2016. He has co-authored industry advisory documents around biospecimen data security and patient engagement in research and currently serves on the board of Professional Responsibility in Medicine & Research (PRIMR).

Dr. Garrick is also on the board of the New York Blood Center where he serves on the Investment Committee. He is Secretary of the board of the American Psychiatric Association Foundation and was Vice Chair of the Board of Regents of Samuel Merritt University. Previously, he served on the \$6BN Bay Area Division of Sutter Health, the board of Quorum Review IRB where he chaired the Compensation Committee, the board of the American Medical Association Foundation where he was Board President and Context Matters Inc (acquired by Decision Resources Group). These entities yielded double digit annual growth during his involvement.

Dr. Garrick earned his MD from Yale School of Medicine and his MBA from Wharton School of Business. He holds an AB in Psychology from Princeton University and resides in Oakland, CA with his wife and three sons.

Shortened version last updated 3/28/19:

Owen Garrick, MD MBA

Owen Garrick, MD MBA is President & CEO of Bridge Clinical Research (BCR). BCR is a global clinical research and health communications firm focused on drug development, scientific advancement and patient engagement. It is active in multiple therapeutic areas including anti-infectives, autoimmune, cardiovascular disease, endocrinology and oncology. At BCR, Dr. Garrick, leads the Clinical Trials, Research Analytics, Health Services Research and Healthcare Communications business units. He has helped launch multiple collaborative efforts in advancing precision medicine research. He serves as an advisor to the Stanford Precision Health for Ethnic and Racial Equity Center (SPHERE) which is one of five NIH centers focused on precision-medicine tools to improve the health of underserved ethnic and racial groups. Dr. Garrick is a Stanford co-investigator for research using Color Genomics tool kits exploring the reasons why patients may or may not participate in genetic testing and is a Stanford sub-awardee for a project specifically focused on the willingness of patients with sickle cell disease to participate in precision medicine research.

Dr. Garrick is a nationally recognized leader in the field of research and research ethics. He is a member of the National Genome Research Institute's (NHGRI) Genomic Education of Healthcare Professionals Partnership. He was appointed to a term as a member of the Department of Health and Human Services Secretary's Advisory Council on Human Research Protections (SACHRP) from 2012-2016 where he co-authored industry advisory documents around biospecimen data security and patient engagement in research. Dr. Garrick currently serves on the Executive Committee of Professional Responsibility in Medicine & Research (PRIMR) and was formerly a member of Quorum Review's IRB. Dr. Garrick earned his MD from Yale School of Medicine and his MBA from Wharton School of Business. He holds an AB in Psychology from Princeton University.